Glaxo’s Eperzan Approved in EU
GlaxoSmithKline ’s ( GSK ) diabetes drug, Eperzan, gained approval in the EU. The European Commission (EC) approved the once-weekly drug both as a monotherapy and as combination therapy in adults suffering from type II diabetes. The EC approved Eperzan on the basis of encouraging data from eight phase III trials on Eperzan […]